PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes, permitting the inhibition or enhancement of protein production. The Company’s lead program, Ataluren (PTC124), is the first investigational new drug designed to enable the formation of a functioning protein in patients with genetic disorders due a nonsense mutation. Ataluren is currently in advanced clinical development for multiple indications, including cystic fibrosis and Duchenne muscular dystrophy.

PTC Therapeutics, Inc.

South Plainfield, NJ

Aragon’s recent discoveries show that the biology of hormone resistant cancers can be overcome through the creation of a new class of nuclear receptor targeting drugs, opening the door to a pipeline of new anti-endocrine therapies. The Company’s approach will produce drugs that are mechanistically distinct from therapies that are either in the clinic or currently being developed.

Aragon Pharmaceuticals, Inc.

San Diego, CA

Igenica is dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. The Company has developed two unique technology platforms, which collectively offer a function-orientated screening strategy to systematically identify new tumor antigens and effective monoclonal antibody drug candidates.

Igenica, Inc.

Burlingame, CA

3-V’s mission is to discover and develop drugs with broad-spectrum antiviral activity and low likelihood of resistance, using a new platform that allows the identification of host proteins as drug targets. Initially, the Company will focus on the discovery and development of drugs against influenza virus, respiratory syncytial virus and rhinovirus.

3-V Biosciences, Inc.

Palo Alto, CA

NGM uses a combination novel experimental approaches to exploit emerging human biology for the development of novel therapies for metabolic and cardiovascular disease. Initially, the Company will focus on the gastrointestinal endocrine system and stem cell biology with a view toward identifying novel factors implicated in type 2 diabetes.

NGM Biopharmaceuticals, Inc.

South San Francisco, CA

Constellation is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science involving selective regulators that are critical to controlling gene expression. While the Company is initially focused on oncology, its technology platform will likely be applicable to other therapeutic areas, including autoimmune, inflammatory and neurological diseases.

Constellation Pharmaceuticals, Inc.

Cambridge, MA

Immune Design is a new generation vaccine company built on emerging understanding of the role of dendritic cells in determining an effective immune response. The Company is employing improved adjuvants and novel technologies that target and control dendritic cells in an unprecedented manner. This approach could create an entirely new generation of prophylactic and therapeutic vaccines for infectious diseases and extend the coverage of current vaccines.

Immune Design Corp.

Seattle, WA